Document is current
Any future updates will be listed below
-
Authors
Trefny, Marcel P. http://orcid.org/0000-0001-6755-7899
Kirchhammer, Nicole http://orcid.org/0000-0001-6043-5143
Auf der Maur, Priska http://orcid.org/0000-0002-9059-8979
Natoli, Marina
Schmid, Dominic http://orcid.org/0000-0003-4821-6495
Germann, Markus
Fernandez Rodriguez, Laura
Herzig, Petra
Lötscher, Jonas
Akrami, Maryam
Stinchcombe, Jane C. http://orcid.org/0000-0003-1459-9299
Stanczak, Michal A.
Zingg, Andreas
Buchi, Melanie
Roux, Julien http://orcid.org/0000-0002-4192-5099
Marone, Romina http://orcid.org/0000-0003-1474-1689
Don, Leyla
Lardinois, Didier
Wiese, Mark
Jeker, Lukas T. http://orcid.org/0000-0002-3359-8796
Bentires-Alj, Mohamed http://orcid.org/0000-0001-6344-1127
Rossy, Jérémie
Thommen, Daniela S. http://orcid.org/0000-0002-7431-2854
Griffiths, Gillian M. http://orcid.org/0000-0003-0434-5842
Läubli, Heinz
Hess, Christoph http://orcid.org/0000-0003-0364-8825
Zippelius, Alfred http://orcid.org/0000-0003-1933-8178
- License Information
-
More Information
Article History
Received: 26 October 2022
Accepted: 12 December 2022
First Online: 2 February 2023
Competing interests
: H.L., A.Zippelius received research funding from Bristol-Myers Squibb and Novartis. A.Zippelius received consulting/advisor fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Hoffmann–La Roche, NBE Therapeutics, Secarna, ACM Pharma, and Hookipa, and maintains further non-commercial research agreements with Secarna, Hookipa, Roche and Beyondsprings. L.T.J. is a co-founder of, holds equity in and has a sponsored research agreement with Cimeio Therapeutics AG. A.Zippelius and M.P.T. have a pending patent application (PCT/EP2022/077391, “Targeting SNX9 rescues recombinant T cell in adoptive therapy”). The remaining authors declare no competing interests.
